Celldex Therapeutics (CLDX) closed at $27.42 on November 20, 2026, down 1.9% from the previous close, on volume of 1,483,527 shares (30-day average 905,084).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 22, 2026 | Call Butterfly (Skip Strike) | 19-Mar-2738 : 50[2x] : 60 C | 240 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Stifel Nicolaus Remains a Buy on Celldex (CLDX)
TipRanks (Fri, 20-Nov 10:15 AM ET)
Celldex (CLDX) Gets a Buy from Cantor Fitzgerald
TipRanks (Fri, 20-Nov 8:38 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Celldex (CLDX)
TipRanks (Fri, 20-Nov 7:06 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), BeOne Medicines (ONC)
TipRanks (Fri, 20-Nov 5:50 AM ET)
Celldex (CLDX) Receives a Buy from Barclays
TipRanks (Fri, 20-Nov 3:35 AM ET)
Celldex declines as it abandons barzolvolimab in atopic dermatitis
Seeking Alpha News (Thu, 19-Nov 5:06 PM ET)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Globe Newswire (Thu, 19-Nov 4:01 PM ET)
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Celldex to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
PRNewswire (Mon, 12-Oct 9:10 AM ET)
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics trades on the NASDAQ stock market under the symbol CLDX.
As of November 20, 2026, CLDX stock price declined to $27.42 with 1,483,527 million shares trading.
CLDX has a beta of 0.71, meaning it tends to be less sensitive to market movements. CLDX has a correlation of 0.04 to the broad based SPY ETF.
CLDX has a market cap of $2.15 billion. This is considered a Mid Cap stock.
Last quarter Celldex Therapeutics reported $0 in Revenue and -$.96 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.05.
In the last 3 years, CLDX traded as high as $53.18 and as low as $14.40.
The top ETF exchange traded funds that CLDX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
CLDX has outperformed the market in the last year with a return of +9.4%, while the SPY ETF gained +6.9%. However, in the most recent history, CLDX shares have underperformed the stock market with its stock returning -31.3% in the last 3 month period and -8.2% for the last 2 week period, while SPY has returned -9.3% and -6.2%, respectively.
CLDX support price is $27.07 and resistance is $28.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDX shares will trade within this expected range on the day.